Brian Skorney
Stock Analyst at Baird
(3.59)
# 944
Out of 5,182 analysts
120
Total ratings
46.51%
Success rate
8.03%
Average return
Main Sectors:
Stocks Rated by Brian Skorney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANRO Alto Neuroscience | Maintains: Outperform | $41 → $38 | $27.16 | +39.91% | 6 | Apr 2, 2026 | |
| XENE Xenon Pharmaceuticals | Maintains: Outperform | $63 → $97 | $56.65 | +71.23% | 2 | Mar 9, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $80 → $88 | $94.31 | -6.69% | 6 | Dec 9, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Neutral | $21 → $15 | $20.64 | -27.33% | 13 | Nov 4, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $58 → $62 | $39.10 | +58.57% | 5 | Sep 26, 2025 | |
| BHVN Biohaven | Maintains: Outperform | $57 → $52 | $10.68 | +386.89% | 4 | Aug 12, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $180 → $186 | $131.18 | +41.79% | 5 | Jul 31, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $105 → $121 | $52.75 | +129.38% | 5 | Jul 11, 2025 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $46 → $32 | $19.67 | +62.68% | 2 | Jun 18, 2025 | |
| BIIB Biogen | Maintains: Outperform | $300 → $255 | $190.07 | +34.16% | 17 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $652 → $587 | $746.58 | -21.37% | 15 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $100 | $132.90 | -24.76% | 3 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $12.96 | +131.48% | 1 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $13.79 | +45.03% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $25.89 | -3.44% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $215 | $345.92 | -37.85% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $6.33 | +342.34% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $39 | $9.34 | +317.56% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $280 → $325 | $437.67 | -25.74% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $29.49 | -66.09% | 2 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $270 | $0.60 | +44,720.72% | 1 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $6 | $4.14 | +44.93% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $300 | $0.61 | +48,736.07% | 3 | May 7, 2018 |
Alto Neuroscience
Apr 2, 2026
Maintains: Outperform
Price Target: $41 → $38
Current: $27.16
Upside: +39.91%
Xenon Pharmaceuticals
Mar 9, 2026
Maintains: Outperform
Price Target: $63 → $97
Current: $56.65
Upside: +71.23%
Mirum Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $80 → $88
Current: $94.31
Upside: -6.69%
Sarepta Therapeutics
Nov 4, 2025
Maintains: Neutral
Price Target: $21 → $15
Current: $20.64
Upside: -27.33%
Crinetics Pharmaceuticals
Sep 26, 2025
Maintains: Outperform
Price Target: $58 → $62
Current: $39.10
Upside: +58.57%
Biohaven
Aug 12, 2025
Maintains: Outperform
Price Target: $57 → $52
Current: $10.68
Upside: +386.89%
Neurocrine Biosciences
Jul 31, 2025
Maintains: Outperform
Price Target: $180 → $186
Current: $131.18
Upside: +41.79%
Soleno Therapeutics
Jul 11, 2025
Maintains: Outperform
Price Target: $105 → $121
Current: $52.75
Upside: +129.38%
Dyne Therapeutics
Jun 18, 2025
Maintains: Outperform
Price Target: $46 → $32
Current: $19.67
Upside: +62.68%
Biogen
May 2, 2025
Maintains: Outperform
Price Target: $300 → $255
Current: $190.07
Upside: +34.16%
Apr 30, 2025
Maintains: Neutral
Price Target: $652 → $587
Current: $746.58
Upside: -21.37%
Feb 12, 2025
Maintains: Neutral
Price Target: $95 → $100
Current: $132.90
Upside: -24.76%
Dec 13, 2024
Initiates: Outperform
Price Target: $30
Current: $12.96
Upside: +131.48%
Nov 26, 2024
Maintains: Outperform
Price Target: $26 → $20
Current: $13.79
Upside: +45.03%
Oct 31, 2024
Initiates: Outperform
Price Target: $25
Current: $25.89
Upside: -3.44%
Sep 25, 2024
Reiterates: Underperform
Price Target: $215
Current: $345.92
Upside: -37.85%
Jun 13, 2024
Initiates: Outperform
Price Target: $28
Current: $6.33
Upside: +342.34%
Mar 6, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $9.34
Upside: +317.56%
May 2, 2023
Maintains: Neutral
Price Target: $280 → $325
Current: $437.67
Upside: -25.74%
Aug 3, 2021
Downgrades: Neutral
Price Target: $10
Current: $29.49
Upside: -66.09%
May 20, 2021
Initiates: Outperform
Price Target: $270
Current: $0.60
Upside: +44,720.72%
Feb 26, 2021
Downgrades: Neutral
Price Target: $18 → $6
Current: $4.14
Upside: +44.93%
May 7, 2018
Maintains: Outperform
Price Target: $600 → $300
Current: $0.61
Upside: +48,736.07%